Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002

• NASDAQ: $CAPR
• Notified: $9.00
• 07:01 EDT